NCT05522868

SB17170 Phase 1 Clinical Trial in Solid Tumors

An Open-label, Multicenter, Phase 1 Clinical Trial to Evaluate MTD, Safety, PK/PD and Preliminary Anti-tumor Activity of SB17170 in Patients With Locally Advanced or Metastatic Solid Tumors Who Have Failed Standard of Care

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: SPARK Biopharma · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

Phase 1 Open-label, multicenter, dose escalation, dose expansion study

Detailed description

This is an open-label, multicenter, Phase 1 clinical trial to evaluate the maximum tolerated dose, safety, pharmacokinetic/pharmacodynamic characteristics and preliminary anti-tumor activity of SB17170 when administered alone(1a) and co-administered with standard of care(1b) to patients with locally advanced or metastatic solid tumors who have failed standard of care. 1 cycle of treatment of this clinical trial is 21 days, and tumors are assessed every 2 cycles.

Conditions

• Solid Tumor

Interventions

Type	Name	Description
DRUG	SB17170	SB17170 capsules, Oral administration 21days/cycle

Timeline

• Start date: 2022-10-17
• Primary completion: 2027-06-30
• Completion: 2027-12-30
• First posted: 2022-08-31
• Last updated: 2025-11-20

Locations

3 sites across 1 country: South Korea